

Ref. No.: EIKO/BSE/2024-25/60

Date: 14th February, 2025.

To, Corporate Services Department, **BSE Limited**, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Newspaper Publication.

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2024 approved at the meeting of Board of Directors held on Wednesday, 12th February, 2025.

- 1. Financial Express (English)
- 2. Mumbai Lakshadweep (Marathi)

Copy of the results are also uploaded on the website of our Company - <u>www.eikolifesciences.com</u>.

Kindly take the same on your records.

Thanking you, Yours sincerely.

For Eiko Lifesciences Limited

Chintan Doshi Compliance officer & Company Secretary Membership No: A36190 Encl: Same as above FRIDAY, FEBRUARY 14, 2025

38

WWW.FINANCIALEXPRESS.COM


FINANCIAL EXPRESS



Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604 EXTRACT OF UNAUDITED STADNALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2024

/F in Lakhe av AFEDS

- 1		1		(P)	ndalone			1	Consolida	Lakhs except EPS)
Sr.		-	Quarter Endec	5555.00		ths Ended	Year Ended	Ousele	r Ended	eo Nine Months Ended
No.	Particulars	31/12/2024	30/9/2024	31/12/2023	31/12/2024	31/12/2023	31/3/2024	31/12/2024	30/9/2024	31/12/2024
2250		and in concerning when their particular and the	(Unaudited)	strated in the second sec	the second se	(Unaudited)	(Audited)	and the second se	(Unaudited)	(Unaudited)
1	Total Income from Operations	701.54	786.98	662.53	2,589.79	1,960.11	2,810.54	758.15	828.58	2,687.99
2	Net profit/ (Loss) for the period before tax (before Exceptional and/ or extraordinary items)	38.08	28.03	29.10	112.23	56.13	98.42	54.12	35.26	135.50
3	Net profit/ (Loss) for the period before tax (After Exceptional and/ or extraordinary items)	38.08	28.03	.29.10	112.23	56.13	98.42	54.12	35.26	135.50
4	Net profit/ (Loss) for the period after tax (After Exceptional and/ or extraordinary items)	28.49	20.81	23.76	83.98	43.85	75.15	39.73	25.78	100.20
5	Net profit after taxes and share of profit of Associates	28.49	20.81	23.76	83.98	43.85	75.15	42.21	28.15	107.50
6	Total comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)	28.49	20.81	23.76	83.98	43.85	77.55	42.21	28.15	107.50
7	Paid up equity share Capital	1,287.28	1,287.28	997.95	1,287.28	997.95	1,287.28	1,287.28	1,287.28	1,287.28
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.		~		(a)	23	3,780.54	2	52	
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.24	0.16	0.24	0.86	0.45	0.73	0.32	0.22	0,82
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.24	0.16	0.24	0.86	0.45	0.73	0.32	0.22	0.82
2 3	and thereafter approved by the board of directors of the company at their mee These financial results have been prepared in accordance with Indian Account Standards) Rules, 2015 (as amended) The above is an extract of the details format of Quarter and Nine Months Er Regulation, 2015. The full format of the Quarter and Nine Months ended F www.eikolifesciences.com	ing Standards	s ("Ind AS") n filed with the	otified under stock excha	Section 133	of the Compa	nies Act 201 of SEBI (list	3 read with th	e Companies s and Disclos	ure Requirements)
¹⁰ ĝ	During the period, the company successfully acquired a 25.01% equity stake i Consolidated financial Results include financial results of: a) Eiko Scientific Solutions LLP- Wholly Owned Subsidiary b) Eikovivify Logistics Private Limited- Subsidiary	n Reflux Pha	maceuticals	Private Limite	ed ("RPPL"), t	hereby makin	g it an assoc	ciate company	of Eiko LifeS	ciences Limited.
0.717.75	c) Reflux Pharmaceuticals Private Limited- Associate Company Consequently, consolidated financial results have been prepared and present consolidated figures for previous financial year are not available.	ed for the cu	rrent financia	l year. Since	this is the f	irst year in w	hich the con			are being reported, ciences Limited
9075-0175 (1990)	c) Reflux Pharmaceuticals Private Limited- Associate Company Consequently, consolidated financial results have been prepared and present consolidated figures for previous financial year are not available.	ed for the cu	rrent financia	l year. Since	this is the f	irst year in w		Fo	r Eiko Lifes	ciences Limited Sd/- Chintan Doshi
Da	c) Reflux Pharmaceuticals Private Limited- Associate Company Consequently, consolidated financial results have been prepared and present	ed for the cu	rrent financia	l year. Since	this is the f	irst year in w		Fo	r Eiko Lifes cretary & Co	ciences Limited Sd/- Chintan Doshi empliance Officer



] [[]

E

1	दि. ३१.१२.२०२४ रोजी संपलेली तिमाही व न	ऊमाहीकरि	ताच्या अल	नेखापरीक्षि	त स्थायी व	व एकत्रित	वित्तीय नि	ष्कर्षांचा स	गरांश		
(रु. लाखांत, ईपीएस										न, ईपीएस वगळता	
		स्थायी						एकत्रित			
अ.	अ. इतप्रशील	तिमाहीअखेर				हीअखेर	वर्षअखेर	तिमाई		नऊमाहीअखेर	
क्र.		39.97.7078	30.09.2028	38.85.5053	38.85.5058	38.85.5053	39.03.2028	39.99.9098	30.09.2028	39.97.7078	
		(अलेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	(लेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	(अलेखापरीक्षित)	
१	परिचालनातून एकूण उत्पन्न	૭૦૧.५૪	૭૮૬.९૮	६६२.५३	२,५८९.७९	१,९६०.११	२,८१०.५४	હ્ય ૮. ૧૫	८२८.५८	२,६८७.९	
२	करपूर्व कालावधीकरिता निव्वळ नफा/(तोटा) (अपवादात्मक व/वा अतिविशेष बाबीपूर्व)	36.06	२८.०३	२९.१०	११२.२३	५६.१३	९८.४२	48.83	રૂપ.રદ્	શ્⊋બ.બ	
÷	करपूर्व कालावधीकरिता निव्वळ नफा/(तोटा) (अपवादात्मक व/वा अतिबिशेष बाबीपरचात)	30.00	२८.०३	२९.१०	११२.२३	५६.१३	९८.४२	૬૪.૧૨	રૂપ.૨૬	શ્⊋બ.બ	
x	करपश्चात कालावधीकरिता निब्बळ नफा/(तोटा) (अपवादात्मक व/वा अतिविशेष बाबीपश्चात)	२८.४९	२०.८१	૨३.७६	८३.९८	४३.८५	હલ, ૧૯	३९.७३	૨५.७૮	१००.२	
4	करपश्चात निव्वळ नफा व सहयोगींच्या नफ्यातील हिस्सा	२८.४९	२०.८१	૨ ૨. હદ્	۲۶.۶۷	૪३.૮५	હલ. ૧૯	४२.२१	૨૮.१५	૨ ૦૭.५	
Ę	कालावधीकरिता एकूण सर्वसमावेशक उत्पन्न (कालावधीकरिताचा (करपश्चात) नफा/(तोटा) व अन्य सर्वसमावेशक उत्पन्न (करपश्चात) यांचा समावेश)	२८.४९	२०.८१	૨३.७६	८३.९८	४३.८५	لصلح، فع فع	४२.२१	૨૮.૧५	<i>ર</i> ાહ ધ્	
Ŀ	प्रदानित समभाग भांडवल	१,२८७.२८	१,२८७.२८	996.94	१,२८७.२८	996.94	१,२८७.२८	१,२८७.२८	શ,૨૮७.૨૮	१, २८७. २	
٤	राखीव (पुनर्मूल्यांकन राखीव वगळता), गत वर्षाच्या लेखापरीक्षित ताळेबंदामध्ये दर्शविल्यानुसार)	-	-	-	-	-	३,७८०.५४	-	-		
٩	मूलभूत उत्पन्न प्रतिशेअर (अवार्षिकीकृत) (ईपीएस रु. मध्ये)	०.२४	०.१६	०.२४	०.८६	0.84	50.0	0.32	०.२२	0.6	
٩	सौम्यीकृत उत्पन्न प्रतिशेअर (अअवार्षिकीकृत) (ईपीएस रु. मध्ये)	0.28	०.१६	०.२४	٥.८६	૦.૪५	50.0	०.३२	0.22	0.6	
ं अ २. स ३. व	१. ३१.१२.२०२४ रोजी संपलेल्या तिमाही व नऊमाहीकरिताचे वरील अलेखामरीक्षित स्थायी व एकत्रित कि ताली आहे. कंफ्नीच्या वैधानिक लेखापरीक्षकांनी बरील निष्कर्षांवर असुधारित मतासह लेखापरीक्षण अहवाल दर वित्तीय निष्कर्ष हे कंप्रन्याकायदा,२०१३ चे अनुच्छेद १३३ सहवाचन कंप्तन्या (भारतीय लेखा मानके) निय रील निष्कर्ष हे सेबी (सूची अनिवार्यता व विमोचन आवश्यकता) विनियमन, २०१५ च्या विनियमन ३३ अंत स्वरोंत्र वेष्याइट www.bseindia.com वर तसेच कंपनीची वेबसाइट www.eikolifesciencescom व	जारी केला आहे. यम, २०१५ (सुधारित र्गत स्टॉक एक्सचेंजव	। केल्यानुसार) अंत	ु र्गत अधिसूचित भाग	स्तीय लेखा मानके ।	(आयएनडी एएस)	यांनुसार तयार कर	ण्यात आले आहे		3.	
	सच बस्ताहर www.beennua.com कर तत्त्व करनाचा वचताहर www.encones.com वर उत्तत्व्य आहत. र कालावधीदप्रयान कंपनीने यशास्वीरीत्वा रेफ्तक्स फार्मास्युटिकल्स प्रायव्हेट लिमिटेड (आरपीणीएल) मधील २५.०१% इक्विटी हिरूयाचे संपादन केले व सदर कंपनी एको लाइफ सायन्सेस लिमिटेडची सहयोगी कंपनी बनली. एकत्रित विलीय निष्कर्षांमध्ये खालील कंपन्यांचे विश क्विट आहेत :									पन्यांचे वित्तीय निष्	
) एको सायन्टीफिक सोल्युशन्स एलएलपी – पूर्णत: स्वामीत्वाची उपकंपनी										